Asieris Announces the World’s First Patient Dose Administered in Combination of Asieris’APL-1202 and BeiGene’s Tislelizumab as Neoadjuvant Therapy for MIBC Patients

Asieris Announces The World's First Patient Dose Administered In Combination Of Asieris'apl 1202 And Beigene's Tislelizumab As Neoadjuvant Therapy For Mibc Patients

Facebook Comments

Leave a Reply

CommentLuv badge